#ASCO14 - Poster: Circulating tumor cell count and lactate dehydrogenase levels are prognostic factors in patients with metastatic CRPC progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial

CHICAGO, IL USA (UroToday.com) - Presented by Howard I. Scher,¹ Karim Fizazi,² Shih Yuan Lee,³ David B. MacLean,³ Iain J. Webb,⁴ Niels Borgstein,³ and Robert Dreicer⁵ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹Memorial Sloan Kettering Cancer Center, New York, NY USA
²Institut Gustave Roussy, University of Paris Sud, Villejuif, France
³Takeda Pharmaceuticals International Co., Cambridge, MA USA
⁴Millennium: The Takeda Oncology Company, Cambridge, MA USA
⁵Cleveland Clinic, Cleveland, OH USA